Company: TAK
Filing Date: 2025-06-25
Form Type: 20-F
Source: 0001395064-25-000095
Chunk: 87

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-25
Form: 20-F
Item: Item 4
Chunk 87
---
 U. S. A., Inc. [Cambridge, MA,      Pharmaceuticals        Research and office                   2,557      Funds on hand/Lease      January 2023              December 2028         
  Construction        Baxalta Belgium Manufacturing S. A.                        Pharmaceuticals        Manufacturing and warehouse (5)      34,125      Funds on hand            February 2022             June 2027             

Notes:

(1) The facility is for the manufacturing of plasma-derived therapies.

(2) Takeda had planned a long-term investment to construct a new manufacturing facility for plasma-derived therapies at the Osaka plant with the total budget of JPY 95 billion. Considering the current circumstances, including a price surge in construction materials partly due to the depreciation of the Japanese yen and the labor shortage among construction companies, during the current fiscal year, Takeda has decided to increase the total planned investment amount and revised the expected commencement and completion schedule.

(3) The facility is for a plasma fractionation capacity expansion.

(4) The budget includes a lease term payment obligation expected to start in 2026 based on a lease agreement we entered into.

(5) The facility is for the manufacturing of plasma-derived therapies.

Environmental Matters

We are subject to laws and regulations concerning the environment, safety matters, regulation of chemicals and product safety in the countries where we manufacture and sell our products or otherwise operate our business. These requirements include regulation of the handling, manufacture, transportation, use and disposal of materials, including the discharge of pollutants into the environment. In the normal course of our business, we are exposed to risks relating to possible releases of hazardous substances into the environment, which could cause environmental or property damage or personal injuries, and which could require remediation of contaminated soil and groundwater, in some cases over many years, regardless of whether the contamination was caused by us, or by previous occupants of the property. See “ Item 3. Key Information - D. Risk Factors - We may incur claims relating to our use, manufacture, handling, storage or disposal of hazardous materials.”

Item 4A. Unresolved Staff Comments